{"filing":{"accession_number":"0001437749-26-019199","cik":"0001091596","ticker":"AURX","company_name":"Nuo Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-03","report_date":null,"primary_document":"aurx20260602_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926019199/aurx20260602_8k.htm"},"events":[{"id":7220,"run_id":6334,"accession_number":"0001437749-26-019199","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Nuo Therapeutics entered into an Amended and Restated Loan and Security Agreement on May 29, 2026, increasing aggregate commitments to $2.0 million with $675,000 funded at interim closing and $325,000 committed for future funding. The transaction involves insider lenders (Scott Pittman, a director and 10%+ owner, and Paul Jacobs, a 5%+ owner), a security interest in all Company assets, and significant warrant dilution (120,125+ immediately exercisable shares plus contingent warrants), representing a material capital structure event.","company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","filing_date":"2026-06-03","form":"8-K","submitted_at":null,"items":[{"id":4045,"accession_number":"0001437749-26-019199","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Company entered into an Amended and Restated Loan and Security Agreement on May 29, 2026, increasing aggregate commitments from the Initial Loan Agreement to $2.0 million total with $675,000 funded at interim closing and $325,000 committed for future funding. While this is a debt financing rather than a traditional M\u0026A transaction, Item 1.01 encompasses \"Entry into a Material Definitive Agreement,\" and the substantial increase in secured debt obligations with warrant issuances affecting equity dilution represents a material capital structure event. The involvement of insiders (Scott Pittman, a director and 10%+ owner, and Paul Jacobs, a 5%+ owner) as lenders, combined with the security interest in all Company assets and significant warrant dilution (120,125+ shares immediately exercisable, plus contingent warrants), makes this material to investors assessing the registrant's financial position and control structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:44:26.505750+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4046,"accession_number":"0001437749-26-019199","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation via an \"Interim Loan Agreement\" incorporated from Item 1.01. Without access to Item 1.01's full details, the nature of this obligation cannot be definitively classified. If the loan is routine financing, it may not be material; if it signals financial distress, covenant concerns, or is a bridge loan preceding restructuring, it could indicate covenant_breach or going_concern risk. The reference structure and \"Interim\" designation suggest potential financial stress, but the limited prose prevents confident assignment to a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:44:26.505750+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4047,"accession_number":"0001437749-26-019199","item_number":"3.02","item_title":"Unregistered Sale of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities by Nuo Therapeutics, specifically multiple series of warrants (Commitment Supplemental Warrants, Origination Interim Warrants, Capital Interim Warrants, and others) plus underlying common stock. The explicit statement that these securities \"have not been registered under the Securities Act\" and the reference to Item 1.01 (which typically covers material acquisitions or financing transactions) indicates a private placement or similar dilutive equity issuance. This is material to investors as it increases share dilution and affects ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:44:26.505750+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4045,"accession_number":"0001437749-26-019199","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The Company entered into an Amended and Restated Loan and Security Agreement on May 29, 2026, increasing aggregate commitments from the Initial Loan Agreement to $2.0 million total with $675,000 funded at interim closing and $325,000 committed for future funding. While this is a debt financing rather than a traditional M\u0026A transaction, Item 1.01 encompasses \"Entry into a Material Definitive Agreement,\" and the substantial increase in secured debt obligations with warrant issuances affecting equity dilution represents a material capital structure event. The involvement of insiders (Scott Pittman, a director and 10%+ owner, and Paul Jacobs, a 5%+ owner) as lenders, combined with the security interest in all Company assets and significant warrant dilution (120,125+ shares immediately exercisable, plus contingent warrants), makes this material to investors assessing the registrant's financial position and control structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:44:26.505750+00:00","company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","filing_date":"2026-06-03"},{"id":4046,"accession_number":"0001437749-26-019199","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.45,"reasoning":"Item 2.03 discloses creation of a direct financial obligation via an \"Interim Loan Agreement\" incorporated from Item 1.01. Without access to Item 1.01's full details, the nature of this obligation cannot be definitively classified. If the loan is routine financing, it may not be material; if it signals financial distress, covenant concerns, or is a bridge loan preceding restructuring, it could indicate covenant_breach or going_concern risk. The reference structure and \"Interim\" designation suggest potential financial stress, but the limited prose prevents confident assignment to a more specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:44:26.505750+00:00","company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","filing_date":"2026-06-03"},{"id":4047,"accession_number":"0001437749-26-019199","item_number":"3.02","item_title":"Unregistered Sale of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities by Nuo Therapeutics, specifically multiple series of warrants (Commitment Supplemental Warrants, Origination Interim Warrants, Capital Interim Warrants, and others) plus underlying common stock. The explicit statement that these securities \"have not been registered under the Securities Act\" and the reference to Item 1.01 (which typically covers material acquisitions or financing transactions) indicates a private placement or similar dilutive equity issuance. This is material to investors as it increases share dilution and affects ownership structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-04T02:44:26.505750+00:00","company_name":"Nuo Therapeutics, Inc.","ticker":"AURX","filing_date":"2026-06-03"}]}